“…TICs were initially identified in acute myeloid leukaemia (AML), and were found capable of inducing AML in immunodeficient mice (Lapidot et al, 1994;Bonnet and Dick, 1997). TICs have since been identified in numerous other tumours, including melanoma, lung, head, neck, pancreatic, prostate, colon, squamous cell cancers, and benign tumours (Collins et al, 2005;Fang et al, 2005;Kim et al, 2005;Dalerba et al, 2007;Prince et al, 2007;Loebinger et al, 2008;Xu et al, 2009). Although the AML TICs resemble and probably originate from the transformation of a stem cell, it is possible that other TICs originate from transformation of early or late progenitor cells.…”